In last trading session, Hepion Pharmaceuticals Inc (NASDAQ:HEPA) saw 12.96 million shares changing hands with its beta currently measuring 1.85. Company’s recent per share price level of $0.48 trading at -$0.01 or -1.44% at ring of the bell on the day assigns it a market valuation of $0.51M. That closing price of HEPA’s stock is at a discount of -30106.25% from its 52-week high price of $144.99 and is indicating a premium of 16.67% from its 52-week low price of $0.40. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.45 million shares which gives us an average trading volume of 1.94 million if we extend that period to 3-months.

For Hepion Pharmaceuticals Inc (HEPA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information

Upright in the red during last session for losing -1.44%, in the last five days HEPA remained trading in the red while hitting it’s week-highest on Tuesday, 04/01/25 when the stock touched $0.48 price level, adding 51.47% to its value on the day. Hepion Pharmaceuticals Inc’s shares saw a change of -97.97% in year-to-date performance and have moved -30.22% in past 5-day. Hepion Pharmaceuticals Inc (NASDAQ:HEPA) showed a performance of -90.59% in past 30-days. Number of shares sold short was 0.16 million shares which calculate 0.34 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 70 to the stock, which implies a rise of 99.31% to its current value. Analysts have been projecting 70 as a low price target for the stock while placing it at a high target of 70. It follows that stock’s current price would drop -14483.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -14483.33% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 63.67% during past 5 years.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s Major holders

Insiders are in possession of 1.96% of company’s total shares while institution are holding 1.48 percent of that, with stock having share float percentage of 1.51%. Investors also watch the number of corporate investors in a company very closely, which is 1.48% institutions for Hepion Pharmaceuticals Inc that are currently holding shares of the company.